[177Lu]Lu-TST001

N/A

Report date: 2025/10/29 10:33:36

Base Information

Drug Name[177Lu]Lu-TST001

Drug Alias Name[177Lu]Lu-TST001

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Lutetium > 177Lu +[4]

Mechanisms of ActionAnti-CLDN18Antibody-dependent cell-mediated cytotoxicity (ADCC) effectsCytotoxic T lymphocytes stimulants

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsStomach NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesTranscenta Holding Ltd

China Registration ClassN/A

Develop Information

Active CompaniesTranscenta Holding Ltd

Inactive CompaniesN/A

Active IndicationsStomach Neoplasms

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A